MedTrace Logo

A Study of S-740792 in Healthy Adult Study Participants

NCT06724978 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2025-10-02

No results posted yet for this study

Summary

This is a 3-part study of S-740792 in healthy adult participants. Part 1 (single-ascending-dose and food effect) will investigate the safety, tolerability, and pharmacokinetics (PK) of S-740792. Part 2 (multiple-ascending-dose and drug-drug interaction) will investigate the safety, tolerability, and PK of S-740792, in addition, the effect of multiple doses of S-740792 on the PK of midazolam. Part 3 will investigate the relative bioavailability of S-740792 tablet compared to S-740792 suspension and the food effect on the PK of the S-740792 tablet.

Conditions

  • Healthy Participants

Interventions

DRUG

S-740792 Suspension

Participants will receive S-740792 as an oral suspension.

DRUG

Midazolam

Participants will receive midazolam as a syrup.

DRUG

Placebo

Participants will receive placebo as an oral suspension.

DRUG

S-740792 Tablet

Participants will receive S-740792 as an oral tablet.

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-21
Primary Completion
2025-09-10
Completion
2025-09-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06724978 on ClinicalTrials.gov